Demographics, treatment regimens and the use of angiotensin-receptor blockers in heart failure: findings from the Valsartan Heart Failure Trial. J Int Med Res 2003;31(5):351-61
Date
11/01/2003Pubmed ID
14587301DOI
10.1177/147323000303100501Scopus ID
2-s2.0-0142211396 (requires institutional sign-in at Scopus site) 3 CitationsAbstract
Heart failure is the only major cardiovascular disease with an incidence and prevalence that continue to increase in the developed world. Early identification and correct treatment of the condition are of paramount importance. In recent years, there has been growing interest in identifying the differences between patients in terms of their risk of heart failure and response to treatment. Differences between men and women, different age groups, patients with varying aetiologies or comorbidities and differences between ethnic groups are only some of the factors that have been identified. This review surveys the available data on differences in responses to treatment, and discusses the use of angiotensin-receptor blockers in heart failure in light of the recent Valsartan Heart Failure Trial (Val-HeFT).
Author List
Majahalme SAuthor
Silja Majahalme MD, PhD Associate Professor in the Medicine department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
Age FactorsAged
Aged, 80 and over
Clinical Trials as Topic
Female
Heart Failure
Humans
Male
Sex Factors
Tetrazoles
Valine
Valsartan
